About
Technology
Issues
FAQ
Search
Scientometrics
Impact Factor
Discipline Ranks
h
-index
g
-index
Articles
Citations
Article Citations
Citation Distribution
Overviews
Top Institutions
Top Schools
Top Authors
Prolific Authors
Top Articles
Citing Bodies
Top Citing Authors
Top Citing Institutions
Top Citing Schools
Top Citing Journals
Top Citing Disciplines
exaly
›
Journals
›
Immunotherapy
›
top-articles
Immunotherapy
2.3
(top 20%)
impact factor
1.6K
(top 10%)
papers
28.4K
(top 10%)
citations
67
(top 10%)
h
-index
2.7
(top 20%)
impact factor
2.2K
all documents
30.6K
doc citations
96
(top 10%)
g
-index
Top Articles
#
Title
Journal
Year
Citations
1
Immunotherapeutic implications of IL-6 blockade for cytokine storm
Immunotherapy
2016
521
2
Tumor-associated macrophages: implications in cancer immunotherapy
Immunotherapy
2017
259
3
Toll-like receptor agonists in cancer therapy
Immunotherapy
2009
258
4
Anti-TNF-α agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls
Immunotherapy
2010
189
5
Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors
Immunotherapy
2020
188
6
PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data
Immunotherapy
2017
162
7
Gold nanoparticles-mediated photothermal therapy and immunotherapy
Immunotherapy
2018
162
8
Recent progress in GM-CSF-based cancer immunotherapy
Immunotherapy
2017
154
9
Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside
Immunotherapy
2016
147
10
Targeting B-cell maturation antigen in multiple myeloma
Immunotherapy
2015
146
11
Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma
Immunotherapy
2015
141
12
Antibody-targeted nanoparticles for cancer therapy
Immunotherapy
2011
140
13
Activation of aryl hydrocarbon receptor by TCDD prevents diabetes in NOD mice and increases Foxp3
+
T cells in pancreatic lymph nodes
Immunotherapy
2009
139
14
Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges
Immunotherapy
2016
139
15
The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis
Immunotherapy
2016
136
16
Naive, effector and memory CD8 T-cell trafficking: parallels and distinctions
Immunotherapy
2011
135
17
Targeting tumor-infiltrating macrophages to combat cancer
Immunotherapy
2013
135
18
Targeting the T-cell co-stimulatory CD27/CD70 pathway in cancer immunotherapy: rationale and potential
Immunotherapy
2015
135
19
Use of allogeneic NK cells for cancer immunotherapy
Immunotherapy
2011
134
20
Immune recognition and rejection of allogeneic skin grafts
Immunotherapy
2011
125
21
Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma
Immunotherapy
2016
124
22
Re-education of macrophages as a therapeutic strategy in cancer
Immunotherapy
2019
124
23
Immunotherapy for Alzheimer’s disease: from anti-β-amyloid to tau-based immunization strategies
Immunotherapy
2012
121
24
MUC1 immunotherapy
Immunotherapy
2010
120
25
Current advances in T-cell-based cancer immunotherapy
Immunotherapy
2014
119
26
Directing dendritic cell immunotherapy towards successful cancer treatment
Immunotherapy
2010
113
27
CD73–adenosine: a next-generation target in immuno-oncology
Immunotherapy
2016
110
28
Anti-inflammatory therapy for diabetic retinopathy
Immunotherapy
2011
109
29
Cancer radioimmunotherapy
Immunotherapy
2011
108
30
mTOR signaling, Tregs and immune modulation
Immunotherapy
2014
108
31
Enhancing tumor T cell infiltration to enable cancer immunotherapy
Immunotherapy
2019
108
32
Etanercept for the treatment of rheumatoid arthritis
Immunotherapy
2018
107
33
Current immunotherapy in rheumatoid arthritis
Immunotherapy
2013
105
34
Eosinophilic count as a biomarker for prognosis of melanoma patients and its importance in the response to immunotherapy
Immunotherapy
2017
104
35
Immunity and immune suppression in human ovarian cancer
Immunotherapy
2011
102
36
Safety analysis of
ex vivo
-expanded NK and NK-like T cells administered to cancer patients: a Phase I clinical study
Immunotherapy
2009
97
37
Dual role of macrophage in tumor immunity
Immunotherapy
2018
97
38
The future of immune checkpoint cancer therapy after PD-1 and CTLA-4
Immunotherapy
2017
94
39
Consequences of B-cell-depleting therapy: hypogammaglobulinemia and impaired B-cell reconstitution
Immunotherapy
2018
93
40
Up to 15-year clinical follow-up of a pilot Phase III immunotherapy study in stage II breast cancer patients using oxidized mannan–MUC1
Immunotherapy
2013
92
41
PD-1/PD-L1 in disease
Immunotherapy
2018
90
42
NK cells: immune cross-talk and therapeutic implications
Immunotherapy
2011
88
43
Cancer-associated fibroblasts as targets for immunotherapy
Immunotherapy
2012
88
44
Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme
Immunotherapy
2014
88
45
Harnessing the power of the immune system via blockade of PD-1 and PD-L1: a promising new anticancer strategy
Immunotherapy
2014
88
46
Combination strategies to enhance antitumor ADCC
Immunotherapy
2012
87
47
Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer
Immunotherapy
2018
86
48
Future perspectives of therapeutic monoclonal antibodies
Immunotherapy
2019
85
49
Hybridoma technologies for antibody production
Immunotherapy
2011
84
50
Myeloid suppressor cells and immune modulation in lung cancer
Immunotherapy
2012
84
site/software ©
exaly
; All materials licenced under
CC by-SA
.